Syntekabio, a global artificial intelligence (AI) drug discovery pioneer, has announced its participation at the upcoming Bio-IT World Conference & Expo.

The company has recently launched its drug discovery services in the US and Europe and is introducing STB LaunchPad, Syntekabio’s proprietary disease-agnostic technology platform that can generate hits, leads, and drug candidates against multiple targets. Viable leads are further optimized and experimentally validated in cooperation with its global network of contract research organizations (CROs), and an IND-enabling package then is delivered to the client.

Jonathan Witztum, PhD, Chief Technology Officer, Syntekabio USA Inc., said, “It is exciting to officially kick off our US activities during BIO-IT World. With our innovative technology and substantial computing power, we can rapidly take clients from target to IND, delivering first- or best-in-class molecules for a wide variety of indications in less than two years. We are excited to now offer these services to customers in the US as well as Europe and look forward to meeting with potential clients to discuss in detail the value our services can bring to their drug discovery and development efforts.”

The company has its supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling.

Syntekabio’s disease-agnostic platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications.